BRIEF published on 03/01/2024 at 13:35, 1 year 9 months ago Hisamitsu America Celebrates 90th Anniversary of Salonpas® with Landmark Sales Achievements Market Growth Pain Relief Hisamitsu America Salonpas Topical Analgesics
BRIEF published on 03/01/2024 at 13:35, 1 year 9 months ago Hisamitsu America célèbre le 90e anniversaire du Salonpas® avec des ventes marquantes Salonpas Hisamitsu Amérique Soulagement De La Douleur Analgésiques Topiques La Croissance Du Marché
PRESS RELEASE published on 03/01/2024 at 13:30, 1 year 9 months ago Hisamitsu America Marks 90 Years of Pioneering Pain Relief with Salonpas(R) with Record Sales Hisamitsu America celebrates 90th anniversary of Salonpas(R) patch, the world's No. 1 OTC topical analgesic brand. Salonpas pioneers transdermal patch tech globally Hisamitsu America Salonpas Patch OTC Topical Analgesics Transdermal Patch Technology Pain Relief Solutions
Published on 12/05/2025 at 02:35, 4 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 22 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 52 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 57 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 7 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 7 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
